Home 5 Articles 5 New LCD Expanding Medicare Coverage for Circulating Tumor Cells Tests Is a Win for Biocept

New LCD Expanding Medicare Coverage for Circulating Tumor Cells Tests Is a Win for Biocept

by | Aug 23, 2021

Biocept announced that it has received expanded Medicare coverage for use of its Target Selector assay to identify HER-2 positive circulating tumor cells under a final CMS local coverage determination (LCD) that took effect on July 4. The New LCD for CTC Tests Although the LCD doesn’t mention any particular test brand or technology by […]

Biocept announced that it has received expanded Medicare coverage for use of its Target Selector assay to identify HER-2 positive circulating tumor cells under a final CMS local coverage determination (LCD) that took effect on July 4. The New LCD for CTC Tests Although the LCD doesn’t mention any particular test brand or technology by […]

This content is Exclusive to Diagnostic Testing and Emerging Technologies Subscribers

Subscribe or Log in for Exclusive Access.